Statements (70)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
various governments
|
| gptkbp:approves |
gptkb:FDA
December 2020 |
| gptkbp:clinical_trial |
44,000
peer-reviewed publications Phase 3 trial Phase 1/2/3 |
| gptkbp:collaboration |
gptkb:Operation_Warp_Speed
|
| gptkbp:community_health |
gptkb:significant
|
| gptkbp:developed_by |
gptkb:Pfizer
gptkb:Bio_NTech |
| gptkbp:distribution |
over 100 countries
|
| gptkbp:dosage_form |
recommended after initial series
|
| gptkbp:dose_schedule |
two doses
|
| gptkbp:emergency_services |
granted in multiple countries
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pfizer-Bio NTech
|
| gptkbp:is_effective_against |
95% in preventing COVID-19
|
| gptkbp:is_vulnerable_to |
academic institutions
generally positive government and private sectors international collaborations ongoing improvements intramuscular injection diverse populations cold chain logistics preventive vaccine ultra-cold freezers logistical hurdles against variants conditional marketing authorization against severe disease long-term effects studies mass vaccination campaigns monitored by health authorities reduction in hospitalizations accelerated process advancements in m RNA technology |
| gptkbp:manufacturing_sites |
multiple locations worldwide
|
| gptkbp:marketed_as |
gptkb:Comirnaty
|
| gptkbp:partnership |
gptkb:Bio_NTech_SE
|
| gptkbp:partnerships |
various health organizations
|
| gptkbp:regulatory_compliance |
gptkb:European_Medicines_Agency
|
| gptkbp:research_focus |
m RNA technology
|
| gptkbp:safety_measures |
ongoing studies
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever chills |
| gptkbp:storage |
-70 degrees Celsius
|
| gptkbp:supply_chain |
global logistics
|
| gptkbp:target_audience |
gptkb:children
adults |
| gptkbp:technology |
lipid nanoparticle delivery system
|
| gptkbp:type |
gptkb:vaccine
|
| gptkbp:used_for |
gptkb:COVID-19
|
| gptkbp:vaccine_accessibility |
efforts to reach underserved communities
|
| gptkbp:vaccine_communication |
public health messaging
|
| gptkbp:vaccine_crisis_response |
rapid development during pandemic
|
| gptkbp:vaccine_data_transparency |
sharing of trial results
|
| gptkbp:vaccine_ethics |
considerations in distribution
|
| gptkbp:vaccine_global_impact |
contribution to herd immunity
|
| gptkbp:vaccine_public_health_strategy |
integrated into national plans
|
| gptkbp:vaccine_regulatory_compliance |
adherence to guidelines
|
| gptkbp:vaccine_updates |
new formulations for variants
|
| gptkbp:bfsParent |
gptkb:COVID-19_Pandemic
gptkb:COVID-19 gptkb:COVID-19_pandemic |
| gptkbp:bfsLayer |
4
|